Adult Survivors of Childhood-onset Steroid-dependent and Steroid-resistant Nephrotic Syndrome Treated with Cyclosporine: a Long-term Single-center Experience

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2023 Aug 23

PMID 37608237

Authors

Yoichi Takemasa

Shuichiro Fujinaga

Mayu Nakagawa

Koji Sakuraya

Daishi Hirano

Affiliations

Soon will be listed here.

Abstract

Background: Although evidence has confirmed that cyclosporine (CS) is efficacious against childhood-onset steroid-dependent and steroid-resistant nephrotic syndrome (SD/SRNS), some patients may continue to relapse during adulthood. However, predictive factors for adult active disease and kidney complications, such as chronic kidney disease (CKD) and hypertension, in this cohort remain unknown.

Methods: We conducted a retrospective study on the long-term outcomes of 81 young adults with childhood-onset SD/SRNS treated with CS. The primary endpoint was the probability of active disease into adulthood. The secondary endpoint was the probability of developing kidney complications.

Results: At the last follow-up (median age, 23.2 years; median disease duration, 15.8 years), 44 adult patients (54%) continued to have active disease, whereas 16 patients developed CKD or hypertension, respectively. The proportion of patients developing kidney complications was similar between the active disease and long-term remission groups. Young age at NS onset and history of relapse during the initial CS (median, 31 months) were independent predictive factors for active disease. Acute kidney injury at NS onset, focal segmental glomerulosclerosis, and irreversible CS nephrotoxicity were identified as risk factors for the development of CKD, whereas older age was identified as a risk factor for the development of CKD and hypertension.

Conclusions: More than 50% of adult survivors treated with CS continued to have active disease, and each 20% developed CKD or hypertension. A long-term follow-up is necessary for patients with SD/SRNS to identify the development of kidney complications later in adulthood that can be attributed to prior disease and CS treatment in childhood, irrespective of disease activity. A higher resolution version of the Graphical abstract is available as Supplementary information.

Citing Articles

To biopsy or not to biopsy a teenager with typical idiopathic nephrotic syndrome? Start steroids first.

Boyer O, Bernardi S, Preka E Pediatr Nephrol. 2024; 40(2):579-585.

PMID: 39259322 DOI: 10.1007/s00467-024-06447-w.

Changes in adverse events after multiple rituximab courses in patients with complicated steroid-dependent nephrotic syndrome.

Morishita T, Fujinaga S Clin Exp Nephrol. 2023; 28(3):261-262.

PMID: 37864679 DOI: 10.1007/s10157-023-02420-3.

References

Hamasaki Y, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K . Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol. 2013; 28(5):765-71. DOI: 10.1007/s00467-012-2393-4. View

Marchel D, Gipson D . Adult survivors of idiopathic childhood onset nephrotic syndrome. Pediatr Nephrol. 2020; 36(7):1731-1737. DOI: 10.1007/s00467-020-04773-3. View

KOSKIMIES O, VILSKA J, Rapola J, HALLMAN N . Long-term outcome of primary nephrotic syndrome. Arch Dis Child. 1982; 57(7):544-8. PMC: 1627702. DOI: 10.1136/adc.57.7.544. View

Trompeter R, Lloyd B, Hicks J, White R, Cameron J . Long-term outcome for children with minimal-change nephrotic syndrome. Lancet. 1985; 1(8425):368-70. DOI: 10.1016/s0140-6736(85)91387-x. View

Lewis M, Baildom E, Davis N, Houston I, Postlethwaite R . Nephrotic syndrome: from toddlers to twenties. Lancet. 1989; 1(8632):255-9. DOI: 10.1016/s0140-6736(89)91266-x. View

Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux M, Landais P . Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis. 2003; 41(3):550-7. DOI: 10.1053/ajkd.2003.50116. View

Ruth E, Kemper M, Leumann E, Laube G, Neuhaus T . Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr. 2005; 147(2):202-7. DOI: 10.1016/j.jpeds.2005.03.050. View

Korsgaard T, Andersen R, Joshi S, Hagstrom S, Rittig S . Childhood onset steroid-sensitive nephrotic syndrome continues into adulthood. Pediatr Nephrol. 2018; 34(4):641-648. DOI: 10.1007/s00467-018-4119-8. View

Takemasa Y, Fujinaga S . Adult chronic kidney disease in childhood-onset nephrotic syndrome. Pediatr Int. 2021; 64(1):e14846. DOI: 10.1111/ped.14846. View

10.

Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Nakanishi K, Matsuyama T . Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol. 2014; 30(3):459-68. DOI: 10.1007/s00467-014-2955-8. View

11.

Fujinaga S, Hirano D, Nishino T, Umeda C, Watanabe Y, Nakagawa M . Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine. Pediatr Nephrol. 2019; 34(11):2417-2421. DOI: 10.1007/s00467-019-04339-y. View

12.

Trautmann A, Boyer O, Hodson E, Bagga A, Gipson D, Samuel S . IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2022; 38(3):877-919. PMC: 9589698. DOI: 10.1007/s00467-022-05739-3. View

13.

Fujinaga S, Hirano D, Murakami H, Ohtomo Y, Shimizu T, Kaneko K . Nephrotoxicity of once-daily cyclosporine A in minimal change nephrotic syndrome. Pediatr Nephrol. 2011; 27(4):671-4. DOI: 10.1007/s00467-011-2076-6. View

14.

Watanabe Y, Fujinaga S, Endo A, Endo S, Nakagawa M, Sakuraya K . Baseline characteristics and long-term outcomes of steroid-resistant nephrotic syndrome in children: impact of initial kidney histology. Pediatr Nephrol. 2020; 35(12):2377-2381. DOI: 10.1007/s00467-020-04760-8. View

15.

Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y . A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol. 2006; 22(1):71-6. DOI: 10.1007/s00467-006-0294-0. View

16.

Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y . Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010; 25(3):539-44. DOI: 10.1007/s00467-009-1377-5. View

17.

Mizutani A, Fujinaga S, Sakuraya K, Hirano D, Shimizu T . Positive effects of single-daily high-dose mizoribine therapy after cyclophosphamide in young children with steroid-dependent nephrotic syndrome. Clin Exp Nephrol. 2018; 23(2):244-250. DOI: 10.1007/s10157-018-1628-5. View

18.

Fujinaga S, Hirano D, Nishizaki N, Someya T, Ohtomo Y, Ohtsuka Y . Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol. 2010; 26(3):479-83. DOI: 10.1007/s00467-010-1707-7. View

19.

Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y . Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child. 2006; 91(8):666-70. PMC: 2083035. DOI: 10.1136/adc.2005.080960. View

20.

Solez K, Colvin R, Racusen L, Haas M, Sis B, Mengel M . Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008; 8(4):753-60. DOI: 10.1111/j.1600-6143.2008.02159.x. View